The production of pharmaceutical ingredients in the Moscow region will be expanded

API-Technology, a part of ChemRar Group, is launching a project to scale up the production of active pharmaceutical ingredients, assist in import substitution and support technological sovereignty of Russia in the field of pharmaceuticals.

Today, when the Russian pharmaceutical industry faces supply chain issues and problems with the purchase of foreign pharmaceutical ingredients required for the manufacture of medicinal products, the only remaining option is to localize the end-to-end manufacture of such products and their pharmaceutical ingredients. In particular, the company is going to establish import-substituting production of the active pharmaceutical ingredient for Elpida — an anti-HIV medicinal product.

API-Technology starts this project under the preferential loan financing program being implemented by the Industrial Development Fund (IDF) of the Russian Federation.

“API-Technology is going to invest up to 410 million rubles in the expansion of the production of active pharmaceutical ingredients. 205 million rubles of these funds are provided by IDF as a preferential loan under the “Development Projects” program. This investment project will also create 50 new jobs. The production facility will be manufacturing ingredients for innovative drugs included in the Vital and Essential Medicines List, which is strategically important for the Russian pharmaceutical industry,” said Ekaterina Zinovieva, Deputy Prime Minister for Investments, Industry and Science of the Moscow Region.

API-Technology is a manufacturing company specializing in end-to-end chemical synthesis of pharmaceutical ingredients. The company, as a strategic division of ChemRar Group, was created to localize the production of pharmaceutical ingredients in the Russian Federation and reduce the import dependence of the Russian pharmaceutical industry.

The production facility is located at ChemRar High Tech Center in Khimki, Moscow Region. This enterprise uses advanced equipment for the synthesis of a wide range of 1 to 100 kg batches of pharmaceutical ingredients. The company currently produces pharmaceutical ingredients for medicines against multiple sclerosis, HIV, and the new coronavirus infection.

ChemRar Group will be able to manufacture up to 10 tons of innovative active pharmaceutical ingredients yearly under this project.